# Takeshi Morimoto

Organization · id `cardio:org-takeshi-morimoto` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov sponsor names](<https://clinicaltrials.gov/search?spons=Takeshi+Morimoto>), retrieved 18 November 2026. No person wrote or checked this page.

## In plain language

An organization that ClinicalTrials.gov lists as a sponsor or collaborator of 10 trials in this atlas.

## Technical summary

Sponsor class other. No ROR record matches the name exactly.

## The registry's words

- Sponsor name: Takeshi Morimoto
- Sponsor class: OTHER

## Connected pages

- Sponsors: Randomized Evaluation of Sirolimus-eluting Versus Everolimus-eluting Stent Trial (`cardio:ct-nct01035450`)
- Sponsors: Clopidogrel High Dose Evaluation for the Patient With Coronary Artery Disease in Japan (`cardio:ct-nct01069302`)
- Sponsors: Evaluation of Routine Follow-up Coronary Angiography After Percutaneous Coronary Intervention Trial (`cardio:ct-nct01123291`)
- Sponsors: Carvedilol Post-intervention Long-term Administration in Large-scale Trial (`cardio:ct-nct01155635`)
- Sponsors: NOBORI Biolimus-Eluting Versus XIENCE/PROMUS Everolimus-eluting Stent Trial (`cardio:ct-nct01303640`)
- Sponsors: Intensive Blood Pressure and LDL Lowering in Diabetic Patients With Coronary Artery Disease (`cardio:ct-nct01422421`)
- Sponsors: Short and Optimal Duration of Dual Antiplatelet Therapy Study (`cardio:ct-nct01659034`)
- Sponsors: Optimal Duration of Anticoagulation Therapy for Isolated Distal Deep Vein Thrombosis in Patients With Cancer Study (`cardio:ct-nct03895502`)
- Sponsors: GOREISAN for Heart Failure (GOREISAN-HF) Trial (`cardio:ct-nct04691700`)
- Sponsors: Efficacy and Safety of Aspirin in Patients With Chronic Coronary Syndromes Without Revascularization (`cardio:ct-nct05347069`)

## Provenance

Content hash: 7de237cd92733e5f59e4d193007d743fd00748405173304bd22ef69edc945eab
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
